Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 4/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.53 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.53 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.53 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.53 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | F10 | P00742 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5974904 | 1.00 | FURIN (0.55) | FURINHDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL4914693 | 1.00 | FURIN (0.55) | FURINHDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL5974680 | 1.00 | FURIN (0.55) | FURINHDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL5974478 | 1.00 | FURIN (0.55) | FURINHDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL5974764 | 0.98 | HDAC3 (0.54) | FURINHDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL5973806 | 0.94 | FURIN (0.54) | FURINHDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL8445590 | 0.93 | FURIN (0.56) | FURINHDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL8446705 | 0.93 | FURIN (0.56) | FURINHDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL6149232 | 0.93 | FURIN (0.56) | FURINHDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL5442050 | 0.93 | FURIN (0.56) | FURINHDAC3HDAC1HDAC2HDAC10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1160240-B1 | Guanylhydrazones for treating inflammatory conditions | CYTOKINE PHARMASCIENCES INC (US) | 2006-11-22 | — | — | EP | disclosed |
| EP-0746312-B1 | GUANYLHYDRAZONES FOR TREATING INFLAMMATORY CONDITIONS | PICOWER INST MED RES (US) | 2002-09-25 | — | — | EP | disclosed |
| US-20020028851-A1 | Aromatic guanylhydrazones (amidinohydrazones) used to prevent and ameliorating cachexia; to inhibit the uptake of arginine by macrophages and/or its conversion to urea; to prevent the generation of nitric oxide (NO) and tumor necrosis factor | BIANCHI MARINA (IT) | 2002-03-07 | — | — | US | disclosed |
| EP-1160240-A1 | Guanylhydrazones for treating inflammatory conditions | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 2001-12-05 | — | — | EP | disclosed |
| US-6248787-B1 | REDUCING CACHEXIA | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH | 2001-06-19 | — | — | US | disclosed |
| US-6180676-B1 | THERAPY FOR CACHEXIA | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH | 2001-01-30 | — | — | US | disclosed |
| US-6022900-A | Guanylhydrazones and their use to treat inflammatory conditions | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 2000-02-08 | — | — | US | disclosed |
| US-6008255-A | TREATING ENDOTOXIC SHOCK BY ADMINISTERING COMPOUNDS OF GIVEN FORMULA WHICH ARE AROMATICS SUBSTITUTED WITH MULTIPLE GUANYLHYDRAZONE MOIETIES, MORE PROPERLY TERMED AMIDINOHYDRAZONES (H2N-C(=NH)-NH-N=) | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1999-12-28 | — | — | US | disclosed |
| US-5859062-A | ADMINISTERING TO TREAT INFLAMMATORY DISEASES MEDIATED BY TUMOR NECROSIS FACTOR | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1999-01-12 | — | — | US | disclosed |
| US-5854289-A | Guanylhydrazones and their use to treat inflammatory conditions | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1998-12-29 | — | — | US | disclosed |
| US-5849794-A | Guanylhydrazones and their use to treat inflammatory conditions | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1998-12-15 | — | — | US | disclosed |
| US-5753684-A | Guanylhydrazones and their use to treat inflammatory conditions | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1998-05-19 | — | — | US | disclosed |
| US-5750573-A | PREVENTING AND TREATING CACHEXIA, THE CLINICAL SYNDROME OF POOR NUTRITION AND BODILY WASTING ASSOCIATED WITH CANCER AND CHRONIC DISEASES; ARGINASE INHIBITORS | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1998-05-12 | — | — | US | disclosed |
| US-5599984-A | AROMATIC AMIDINOHYDRAZONES AS INHIBITORS FOR THE UPTAKE OF ARGININE BY MACROPHAGES AND/OR ITS CONVERSION TO UREA; PREVENTION OF NITRIC OXIDE GENERATION; CACHEXIA; METABOLIC SYNDROMES | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1997-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028851-A1 | Aromatic guanylhydrazones (amidinohydrazones) used to prevent and ameliorating cachexia; to inhibit the uptake of arginine by macrophages and/or its conversion to urea; to prevent the generation of nitric oxide (NO) and tumor necrosis factor | ARG1, ARG2, NOS3 | FURIN 3866/4885HDAC3 1177/4885HDAC1 1114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.